



Contacts: Tran Nguyen / CFO
Somaxon Pharmaceuticals, Inc.
(858) 876-6500

Rob Whetstone
PondelWilkinson, Inc.
(310) 279-5963

Investors@somaxon.com

**SOMAXON PHARMACEUTICALS TO PRESENT AT THE BMO CAPITAL
MARKETS 10TH ANNUAL FOCUS ON HEALTHCARE CONFERENCE**

SAN DIEGO, CA – July 29, 2010 – Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) today announced that Richard W. Pascoe, Somaxon's president and chief executive officer, will present at the BMO Capital Markets 10th Annual Focus on Healthcare Conference at The Sheraton New York Hotel and Towers in New York City on Thursday, August 5th at 10:45 a.m. Eastern Time.

A live webcast of the presentation will be available in the Investor Relations section of the company's Web site under Event Scheduler at www.somaxon.com. The webcast will be archived and accessible for 6 months following the conference.

About Somaxon Pharmaceuticals, Inc.

Headquartered in San Diego, CA, Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and of late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area. Somaxon's product Silenor® (doxepin) has been approved by the FDA for the treatment of insomnia characterized by difficulty with sleep maintenance.

For more information, please visit the company's web site at www.somaxon.com.

###